rofecoxib has been researched along with Adenomatous Polyposis Coli in 8 studies
Adenomatous Polyposis Coli: A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, Long-term use of rofecoxib is well tolerated and effective in inhibiting polyp formation in polyposis patients." | 2.71 | Rofecoxib reduces polyp recurrence in familial polyposis. ( Alon-Baron, L; Arber, N; Brazowski, E; Bulvik, B; Hallak, A; Halpern, Z; Moshkowitz, M; Shamir, R, 2003) |
| "Celecoxib has shown benefit in regressing colorectal adenomas and appears to have some duodenal activity as well." | 1.35 | Chemoprevention with special reference to inherited colorectal cancer. ( Lynch, PM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zagani, R | 1 |
| Hamzaoui, N | 1 |
| Cacheux, W | 1 |
| de Reyniès, A | 1 |
| Terris, B | 1 |
| Chaussade, S | 1 |
| Romagnolo, B | 1 |
| Perret, C | 1 |
| Lamarque, D | 1 |
| Almendingen, K | 1 |
| Larsen, LN | 1 |
| Fausa, O | 1 |
| Bratlie, J | 1 |
| Høstmark, AT | 1 |
| Aabakken, L | 1 |
| Higuchi, T | 1 |
| Iwama, T | 1 |
| Yoshinaga, K | 1 |
| Toyooka, M | 1 |
| Taketo, MM | 1 |
| Sugihara, K | 1 |
| Hallak, A | 1 |
| Alon-Baron, L | 1 |
| Shamir, R | 1 |
| Moshkowitz, M | 1 |
| Bulvik, B | 1 |
| Brazowski, E | 1 |
| Halpern, Z | 1 |
| Arber, N | 1 |
| Kashfi, K | 1 |
| Rigas, B | 1 |
| Grösch, S | 1 |
| Maier, TJ | 1 |
| Schiffmann, S | 1 |
| Geisslinger, G | 1 |
| Lynch, PM | 1 |
| FitzGerald, GA | 1 |
2 reviews available for rofecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Is COX-2 a 'collateral' target in cancer prevention?
Topics: Adenomatous Polyposis Coli; Anticarcinogenic Agents; Cyclooxygenase Inhibitors; Epoprostenol; Humans | 2005 |
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
3 trials available for rofecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygen | 2010 |
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Topics: Adenomatous Polyposis Coli; Adult; Colonic Polyps; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2003 |
Rofecoxib reduces polyp recurrence in familial polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Apoptosis; Cell Division; Colonoscopy; Cyclooxygenase Inhibitors; | 2003 |
3 other studies available for rofecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Topics: Adenomatous Polyposis Coli; Animals; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Cell Sur | 2009 |
Chemoprevention with special reference to inherited colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ascorbic | 2008 |
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Syste | 2002 |